|
1
|
Walton C, King R, Rechtman L, Kaye W,
Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der
Mei I, et al: Rising prevalence of multiple sclerosis worldwide:
Insights from the Atlas of MS, third edition. Mult Scler J.
26:1816–1821. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chiurchiù V, van der Stelt M, Centonze D
and Maccarrone M: The endocannabinoid system and its therapeutic
exploitation in multiple sclerosis: Clues for other
neuroinflammatory diseases. Prog Neurobiol. 160:82–100.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ghasemi N, Razavi S and Nikzad E: Multiple
sclerosis: Pathogenesis, symptoms, diagnoses and cell-based
therapy. Cell J. 19:1–10. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nishanth K, Tariq E, Nzvere FP, Miqdad M
and Cancarevic I: Role of smoking in the pathogenesis of multiple
sclerosis: A review article. Cureus. 12(e9564)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pfeuffer S, Kerschke L, Ruck T, Rolfes L,
Pawlitzki M, Albrecht P, Wiendl H and Meuth SG: Teriflunomide
treatment is associated with optic nerve recovery in early multiple
sclerosis. Ther Adv Neurol Disord.
14(1756286421997372)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Manouchehrinia A, Tench CR, Maxted J,
Bibani RH, Britton J and Constantinescu CS: Tobacco smoking and
disability progression in multiple sclerosis: United Kingdom cohort
study. Brain. 2013;136(Pt 7):2298–2304. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Stoiloudis P, Kesidou E, Bakirtzis C,
Sintila SA, Konstantinidou N, Boziki M and Grigoriadis N: The role
of diet and interventions on multiple sclerosis: A review.
Nutrients. 14(1150)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sameer AS and Nissar S: Toll-Like
receptors (TLRs): Structure, functions, signaling, and role of
their polymorphisms in colorectal cancer susceptibility. Biomed Res
Int. 2021(1157023)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sloane JA, Batt C, Ma Y, Harris ZM, Trapp
B and Vartanian T: Hyaluronan blocks oligodendrocyte progenitor
maturation and remyelination through TLR2. Proc Natl Acad Sci USA.
107:11555–11560. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu Y, Yin H, Zhao M and Lu Q: TLR2 and
TLR4 in autoimmune diseases: A comprehensive review. Clin Rev
Allergy Immunol. 47:136–147. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shaw PJ, Barr MJ, Lukens JR, McGargill MA,
Chi H, Mak TW and Kanneganti TD: Signaling via the RIP2 adaptor
protein in central nervous system-infiltrating dendritic cells
promotes inflammation and autoimmunity. Immunity. 34:75–84.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Constantinescu CS, Farooqi N, O'Brien K
and Gran B: Experimental autoimmune encephalomyelitis (EAE) as a
model for multiple sclerosis (MS). Br J Pharmacol. 164:1079–1106.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mahmoudi M, Rastin M, Kazemi Arababadi M,
Anaeigoudari A and Nosratabadi R: Enhancing the efficacy of
Hypericum perforatum in the treatment of an experimental model of
multiple sclerosis using gold nanoparticles: An in vivo study.
Avicenna J Phytomedicine. 12:325–336. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Andersson Å, Covacu R, Sunnemark D,
Danilov AI, Dal Bianco A, Khademi M, Wallström E, Lobell A, Brundin
L, Lassmann H and Harris RA: Pivotal Advance: HMGB1 expression in
active lesions of human and experimental multiple sclerosis. J
Leukoc Biol. 84:1248–1255. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Reynolds JM, Martinez GJ, Chung Y and Dong
C: Toll-like receptor 4 signaling in T cells promotes autoimmune
inflammation. Proc Natl Acad Sci USA. 109:13064–13069.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bustamante MF, Fissolo N, Río J, Espejo C,
Costa C, Mansilla MJ, Lizasoain I, Moro MA, Carmen Edo M, Montalban
X and Comabella M: Implication of the toll-like receptor 4 pathway
in the response to interferon-β in multiple sclerosis. Ann Neurol.
70:634–645. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zheng C, Chen J, Chu F, Zhu J and Jin T:
Inflammatory Role of TLR-MyD88 signaling in multiple sclerosis.
Front Mol Neurosci. 12(314)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Marta M, Meier UC and Lobell A: Regulation
of autoimmune encephalomyelitis by toll-like receptors. Autoimmun
Rev. 8:506–509. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Deguine J and Barton GM: MyD88: A central
player in innate immune signaling. F1000Prime Rep.
6(97)2014.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Lee YK, Kang M and Choi EY:
TLR/MyD88-mediated innate immunity in intestinal graft-versus-host
disease. Immune Netw. 17:144–151. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lai CY, Su YW, Lin KI, Hsu LC and Chuang
TH: Natural modulators of endosomal toll-like receptor-mediated
psoriatic skin inflammation. J Immunol Res.
2017(7807313)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liu X, Wang T, Liu X, Ji Z, Men Y, Du M,
Ding C, Wu Y, Liu X and Kang Q: Antitumor and immunomodulatory
effects of recombinant fusion protein rMBP-NAP through TLR-2
dependent mechanism in tumor bearing mice. Int Immunopharmacol.
2015. 29:876–883. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gambuzza M, Licata N, Palella E, Celi D,
Foti Cuzzola V, Italiano D, Marino S and Bramanti P: Targeting
toll-like receptors: Emerging therapeutics for multiple sclerosis
management. J Neuroimmunol. 239:1–12. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Arslan F, Houtgraaf JH, Keogh B, Kazemi K,
De Jong R, McCormack WJ, O'Neill LA, McGuirk P, Timmers L, Smeets
MB, et al: Treatment with OPN-305, a humanized anti-toll-like
receptor-2 antibody, reduces myocardial ischemia/reperfusion injury
in pigs. Circ Cardiovasc Interv. 5:279–287. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
O'Neill LAJ, Hennessy EJ and Parker AE:
Targeting Toll-like receptors: Emerging therapeutics? Nat Rev Drug
Discov. 9:293–307. 2010.
|
|
27
|
Church JS, Milich LM, Lerch JK, Popovich
PG and McTigue DM: E6020, a synthetic TLR4 agonist, accelerates
myelin debris clearance, Schwann cell infiltration, and
remyelination in the rat spinal cord. Glia. 65:883–899.
2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gooshe M, Abdolghaffari AH, Gambuzza ME
and Rezaei N: The role of toll-like receptors in multiple sclerosis
and possible targeting for therapeutic purposes. Rev Neurosci.
25:713–739. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Baig MS, Roy A, Saqib U, Rajpoot S,
Srivastava M, Naim A, Liu D, Saluja R, Faisal SM, Pan Q, et al:
Repurposing thioridazine (TDZ) as an anti-inflammatory agent. Sci
Rep. 8(12471)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bonetti B, Stegagno C, Cannella B, Rizzuto
N, Moretto G and Raine CS: Activation of NF-κB and c-jun
transcription factors in multiple sclerosis lesions: Implications
for oligodendrocyte pathology. Am J Pathol. 155:1433–1438.
1999.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gveric D, Kaltschmidt C, Cuzner ML and
Newcombe J: Transcription Factor NF-kappaB and Inhibitor
IkappaBalpha are localized in macrophages in active multiple
sclerosis lesions. J Neuropathol Exp Neurol. 57:168–178.
1998.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Housley WJ, Fernandez SD, Vera K,
Murikinati SR, Grutzendler J, Cuerdon N, Glick L, De Jager PL,
Mitrovic M, Cotsapas C and Hafler DA: Genetic variants associated
with autoimmunity drive NFκB signaling and responses to
inflammatory stimuli. Sci Transl Med. 7(291ra93)2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Arellano G, Acuña E, Reyes LI, Ottum PA,
De Sarno P, Villarroel L, Ciampi E, Uribe-San Martín R, Cárcamo C
and Naves R: Th1 and Th17 cells and associated cytokines
discriminate among clinically isolated syndrome and multiple
sclerosis phenotypes. Front Immunol. 8(753)2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Becher B and Segal BM: T H17 cytokines in
autoimmune neuro-inflammation. Curr Opin Immunol. 23:707–712.
2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Segal BM, Dwyer BK and Shevach EM: An
interleukin (IL)-10/IL-12 immunoregulatory circuit controls
susceptibility to autoimmune disease. J Exp Med. 187:537–546.
1998.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Panitch HS, Hirsch RL, Haley AS and
Johnson KP: Exacerbations of multiple sclerosis in patients treated
with gamma interferon. Lancet. 1:893–895. 1987.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Nicoletti F, Patti F, Cocuzza C, Zaccone
P, Nicoletti A, Di Marco R and Reggio A: Elevated serum levels of
interleukin-12 in chronic progressive multiple sclerosis. J
Neuroimmunol. 70:87–90. 1996.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Alboni S, Cervia D, Sugama S and Conti B:
Interleukin 18 in the CNS. J Neuroinflammation. 7(9)2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Weinstock JV, Blum A, Metwali A, Elliott D
and Arsenescu R: IL-18 and IL-12 signal through the NF-kappa B
pathway to induce NK-1R expression on T cells. J Immunol.
170:5003–5007. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Karni A, Koldzic DN, Bharanidharan P,
Khoury SJ and Weiner HL: IL-18 is linked to raised IFN-gamma in
multiple sclerosis and is induced by activated CD4(+) T cells via
CD40-CD40 ligand interactions. J Neuroimmunol. 125:134–140.
2002.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sica A, Dorman L, Viggiano V, Cippitelli
M, Ghosh P, Rice N and Young HA: Interaction of NF-kappaB and NFAT
with the interferon-gamma promoter. J Biol Chem. 272:30412–30420.
1997.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Nicoletti F, Di Marco R, Mangano K, Patti
F, Reggio E, Nicoletti A, Bendtzen K and Reggio A: Increased serum
levels of interleukin-18 in patients with multiple sclerosis.
Neurology. 57:342–344. 2001.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wildbaum G, Youssef S, Grabie N and Karin
N: Neutralizing antibodies to IFN-gamma-inducing factor prevent
experimental autoimmune encephalomyelitis. J Immunol.
161:6368–6374. 1998.PubMed/NCBI
|
|
44
|
Losy J and Niezgoda A: IL-18 in patients
with multiple sclerosis. Acta Neurol Scand. 104:171–173.
2001.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Sun SC, Chang JH and Jin J: Regulation of
nuclear factor-κB in autoimmunity. Trends Immunol. 34:282–289.
2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Yang XO, Pappu BP, Nurieva R, Akimzhanov
A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, et
al: T helper 17 lineage differentiation is programmed by orphan
nuclear receptors ROR alpha and ROR gamma. Immunity. 28:29–39.
2008.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tzartos JS, Friese MA, Craner MJ, Palace
J, Newcombe J, Esiri MM and Fugger L: Interleukin-17 production in
central nervous system-infiltrating T cells and glial cells is
associated with active disease in multiple sclerosis. Am J Pathol.
172:146–155. 2008.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Durelli L, Conti L, Clerico M, Boselli D,
Contessa G, Ripellino P, Ferrero B, Eid P and Novelli F: T-helper
17 cells expand in multiple sclerosis and are inhibited by
interferon-beta. Ann Neurol. 65:499–509. 2009.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Muls N, Jnaoui K, Dang HA, Wauters A, van
Snick J, Sindic CJ and van Pesch V: Upregulation of IL-17, but not
of IL-9, in circulating cells of CIS and relapsing MS patients.
Impact of corticosteroid therapy on the cytokine network. J
Neuroimmunol. 243:73–80. 2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sutton C, Brereton C, Keogh B, Mills KH
and Lavelle EC: A crucial role for interleukin (IL)-1 in the
induction of IL-17-producing T cells that mediate autoimmune
encephalomyelitis. J Exp Med. 203:1685–1691. 2006.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Dujmovic I, Mangano K, Pekmezovic T,
Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F and Drulovic
J: The analysis of IL-1 beta and its naturally occurring inhibitors
in multiple sclerosis: The elevation of IL-1 receptor antagonist
and IL-1 receptor type II after steroid therapy. J Neuroimmunol.
207:101–106. 2009.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Badovinac V, Mostarica-Stojković M,
Dinarello CA and Stošić-Grujičić S: Interleukin-1 receptor
antagonist suppresses experimental autoimmune encephalomyelitis
(EAE) in rats by influencing the activation and proliferation of
encephalitogenic cells. J Neuroimmunol. 85:87–95. 1998.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Xiao Y, Jin J, Chang M, Nakaya M, Hu H,
Zou Q, Zhou X, Brittain GC, Cheng X and Sun SC: TPL2 mediates
autoimmune inflammation through activation of the TAK1 axis of
IL-17 signaling. J Exp Med. 211:1689–1702. 2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Komiyama Y, Nakae S, Matsuki T, Nambu A,
Ishigame H, Kakuta S, Sudo K and Iwakura Y: IL-17 plays an
important role in the development of experimental autoimmune
encephalomyelitis. J Immunol. 177:566–573. 2006.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Haak S, Croxford AL, Kreymborg K, Heppner
FL, Pouly S, Becher B and Waisman A: IL-17A and IL-17F do not
contribute vitally to autoimmune neuro-inflammation in mice. J Clin
Invest. 119:61–69. 2009.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Sonderegger I, Kisielow J, Meier R, King C
and Kopf M: IL-21 and IL-21R are not required for development of
Th17 cells and autoimmunity in vivo. Eur J Immunol. 38:1833–1838.
2008.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Kreymborg K, Etzensperger R, Dumoutier L,
Haak S, Rebollo A, Buch T, Heppner FL, Renauld JC and Becher B:
IL-22 is expressed by Th17 Cells in an IL-23-Dependent fashion, but
not required for the development of autoimmune encephalomyelitis. J
Immunol. 179:8098–8104. 2007.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Leibowitz SM and Yan J: NF-κB pathways in
the pathogenesis of multiple sclerosis and the therapeutic
implications. Front Mol Neurosci. 9(84)2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Lebman DA and Spiegel S: Cross-talk at the
crossroads of sphingosine-1-phosphate, growth factors, and cytokine
signaling. J Lipid Res. 49:1388–1394. 2008.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Colombo E, Di Dario M, Capitolo E,
Chaabane L, Newcombe J, Martino G and Farina C: Fingolimod may
support neuroprotection via blockade of astrocyte nitric oxide. Ann
Neurol. 76:325–337. 2014.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Spiegel S and Milstien S: The outs and the
ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol.
11:403–415. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Takabe K, Paugh SW, Milstien S and Spiegel
S: Inside-out signaling of sphingosine-1-phosphate: Therapeutic
targets. Pharmacol Rev. 60:181–195. 2008.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Kim JH, Kim JH, Song WK, Kim JH and Chun
JS: Sphingosine 1-phosphate activates Erk-1/-2 by transactivating
epidermal growth factor receptor in Rat-2 cells. IUBMB Life.
50:119–124. 2000.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Napolitano G and Karin M: Sphingolipids:
The Oil on the TRAFire that promotes inflammation. Sci Signal.
3(pe34)2010.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Yopp AC, Ochando JC, Mao M, Ledgerwood L,
Ding Y and Bromberg JS: Sphingosine 1-Phosphate receptors regulate
chemokine-driven transendothelial migration of lymph node but not
splenic T cells. J Immunol. 175:2913–2924. 2005.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Honig SM, Fu S, Mao X, Yopp A, Gunn MD,
Randolph GJ and Bromberg JS: FTY720 stimulates multidrug
transporter- and cysteinyl leukotriene-dependent T cell chemotaxis
to lymph nodes. J Clin Invest. 111:627–637. 2003.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Pham TH, Okada T, Matloubian M, Lo CG and
Cyster JG: S1P1 Receptor signaling overrides retention mediated by
G alpha i-Coupled receptors to promote T cell egress. Immunity.
28:122–133. 2008.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Bridel C and Lalive PH: Update on multiple
sclerosis treatments. Swiss Med Wkly. 144(w14012)2014.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Warnke C, Zu Hörste GM, Hartung HP, Stüve
O and Kieseier BC: Review of teriflunomide and its potential in the
treatment of multiple sclerosis. Neuropsychiatr Dis Treat.
5:333–340. 2009.PubMed/NCBI
|
|
70
|
Manna SK and Aggarwal BB:
Immunosuppressive leflunomide metabolite (A77 1726) blocks
TNF-dependent nuclear factor-kappa B activation and gene
expression. J Immunol. 162:2095–2102. 1999.PubMed/NCBI
|
|
71
|
Cua DJ and Tato CM: Innate IL-17-producing
cells: The sentinels of the immune system. Nat Rev Immunol.
10:479–489. 2010.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Infante-Duarte C, Horton HF, Byrne MC and
Kamradt T: Microbial lipopeptides induce the production of IL-17 in
Th cells. J Immunol. 165:6107–6115. 2000.PubMed/NCBI View Article : Google Scholar
|
|
73
|
McGeachy MJ, Cua DJ and Gaffen SL: The
IL-17 family of cytokines in health and disease. Immunity.
50:892–906. 2019.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Kolbinger F, Huppertz C, Mir A and Padova
F: IL-17A and multiple sclerosis: Signaling pathways, producing
cells and target cells in the central nervous system. Curr Drug
Targets. 17:1882–1893. 2016.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Luzza F, Parrello T, Monteleone G, Sebkova
L, Romano M, Zarrilli R, Imeneo M and Pallone F: Up-Regulation of
IL-17 is associated with bioactive IL-8 expression in helicobacter
pylori-infected human gastric mucosa. J Immunol. 165:5332–5337.
2000.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Kostic M, Dzopalic T, Zivanovic S,
Zivkovic N, Cvetanovic A, Stojanovic I, Vojinovic S, Marjanovic G,
Savic V and Colic M: IL-17 and glutamate excitotoxicity in the
pathogenesis of multiple sclerosis. Scand J Immunol. 79:181–186.
2014.PubMed/NCBI View Article : Google Scholar
|
|
77
|
González H and Pacheco R: T-cell-mediated
regulation of neuroinflammation involved in neurodegenerative
diseases. J Neuroinflammation. 11(201)2014.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Gu C, Wu L and Li X: IL-17 family:
Cytokines, receptors and signaling. Cytokine. 64:477–485.
2013.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Saadeldin MK: Highlights from the
‘Noncoding RNA world : From Mechanism to Therapy’ conference. wasj.
3(64)2021.
|
|
80
|
Jin M, Akgün K, Ziemssen T, Kipp M,
Günther R and Hermann A: Interleukin-17 and th17 lymphocytes
directly impair motoneuron survival of wildtype and FUS-ALS mutant
human iPSCs. Int J Mol Sci. 22(8042)2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Ransohoff RM: How neuroinflammation
contributes to neurodegeneration. Science. 353:777–783.
2016.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Zimmermann J, Krauthausen M, Hofer MJ,
Heneka MT, Campbell IL and Müller M: CNS-targeted production of
IL-17A induces glial activation, microvascular pathology and
enhances the neuroinflammatory response to systemic endotoxemia.
PLoS One. 8(e57307)2013.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Rodgers JM, Robinson AP, Rosler ES,
Lariosa-Willingham K, Persons RE, Dugas JC and Miller SD: IL-17A
activates ERK1/2 and enhances differentiation of oligodendrocyte
progenitor cells. Glia. 63:768–779. 2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Chen J, Liu X and Zhong Y:
Interleukin-17A: The key cytokine in neurodegenerative diseases.
Front Aging Neurosci. 12(566922)2020.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Singh NP, Hegde VL, Hofseth LJ, Nagarkatti
M and Nagarkatti PS: Resveratrol (trans-3,5,4'-trihydroxystilbene)
ameliorates experimental allergic encephalomyelitis, primarily via
induction of apoptosis in T cells involving activation of aryl
hydrocarbon receptor and estrogen receptor. Mol Pharmacol.
72:1508–1521. 2007.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Wang J, Chen F, Zheng P, Deng W, Yuan J,
Peng B, Wang R, Liu W, Zhao H, Wang Y and Wu G: Huperzine A
ameliorates experimental autoimmune encephalomyelitis via the
suppression of T cell-mediated neuronal inflammation in mice. Exp
Neurol. 236:79–87. 2012.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Zhao X, Kan Q, Zhu L and Zhang GX: Matrine
suppresses production of IL-23/IL-17 and ameliorates experimental
autoimmune encephalomyelitis. Am J Chin Med. 39:933–941.
2011.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Sanadgol N, Golab F, Tashakkor Z, Taki N,
Moradi Kouchi S, Mostafaie A, Mehdizadeh M, Abdollahi M, Taghizadeh
G and Sharifzadeh M: Neuroprotective effects of ellagic acid on
cuprizone-induced acute demyelination through limitation of
microgliosis, adjustment of CXCL12/IL-17/IL-11 axis and restriction
of mature oligodendrocytes apoptosis. Pharm Biol. 55:1679–1687.
2017.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Kostic M, Zivkovic N, Cvetanovic A,
Stojanovic I and Colic M: IL-17 signalling in astrocytes promotes
glutamate excitotoxicity: Indications for the link between
inflammatory and neurodegenerative events in multiple sclerosis.
Mult Scler Relat Disord. 11:12–17. 2017.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Lock C, Hermans G, Pedotti R, Brendolan A,
Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard
J, et al: Gene-microarray analysis of multiple sclerosis lesions
yields new targets validated in autoimmune encephalomyelitis. Nat
Med. 8:500–508. 2002.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Das Sarma J, Ciric B, Marek R, Sadhukhan
S, Caruso ML, Shafagh J, Fitzgerald DC, Shindler KS and Rostami A:
Functional interleukin-17 receptor A is expressed in central
nervous system glia and upregulated in experimental autoimmune
encephalomyelitis. J Neuroinflammation. 6(14)2009.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Liu G, Guo J, Liu J, Wang Z and Liang D:
Toll-like receptor signaling directly increases functional IL-17RA
expression in neuroglial cells. Clin Immunol. 154:127–140.
2014.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Brelstaff J, Tolkovsky AM, Ghetti B,
Goedert M and Spillantini MG: Living neurons with tau filaments
aberrantly expose phosphatidylserine and are phagocytosed by
microglia. Cell Rep. 24:1939–1948.e4. 2018.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Qin Y, Garrison BS, Ma W, Wang R, Jiang A,
Li J, Mistry M, Bronson RT, Santoro D, Franco C, et al: A milieu
molecule for TGF-β Required for microglia function in the nervous
system. Cell. 174:156–171.e16. 2018.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Li C, Zhao B, Lin C, Gong Z and An X:
TREM2 inhibits inflammatory responses in mouse microglia by
suppressing the PI3K/NF-κB signaling. Cell Biol Int. 43:360–372.
2019.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Jäkel S, Agirre E, Mendanha Falcão A, van
Bruggen D, Lee KW, Knuesel I, Malhotra D, Ffrench-Constant C,
Williams A and Castelo-Branco G: Altered human oligodendrocyte
heterogeneity in multiple sclerosis. Nature. 566:543–547.
2019.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao
J, Chandrasekharan U, DiCorleto PE, Trapp BD, Ransohoff RM and Li
X: Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2
+ glial cells. Nat Neurosci. 16:1401–1408. 2013.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Paintlia MK, Paintlia AS, Singh AK and
Singh I: Synergistic activity of interleukin-17 and tumor necrosis
factor-α enhances oxidative stress-mediated oligodendrocyte
apoptosis. J Neurochem. 116:508–521. 2011.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Romanenko M, Kholin V, Koliada A and
Vaiserman A: Nutrition, gut microbiota, and Alzheimer's disease.
Front Psychiatry. 12(712673)2021.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Bagur MJ, Antonia Murcia M,
Jiménez-Monreal AM, Tur JA, Bibiloni MM, Alonso GL and
Martínez-Tomé M: Influence of diet in multiple sclerosis: A
systematic review. Adv Nutr. 8:463–472. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Mao XY, Yin XX, Guan QW, Xia QX, Yang N,
Zhou HH, Liu ZQ and Jin WL: Dietary nutrition for neurological
disease therapy: Current status and future directions. Pharmacol
Ther. 226(107861)2021.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Mao P and Reddy PH: Is multiple sclerosis
a mitochondrial disease? Biochim Biophys Acta. 1802:66–79.
2010.PubMed/NCBI View Article : Google Scholar
|
|
103
|
de Almeida NM, Wessels HJ, de Graaf RM,
Ferousi C, Jetten MS, Keltjens JT and Kartal B: Membrane-bound
electron transport systems of an anammox bacterium: A complexome
analysis. Biochim Biophys Acta. 1857:1694–1704. 2016.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Nakagawa T, Shimizu S, Watanabe T,
Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T and Tsujimoto Y:
Cyclophilin D-dependent mitochondrial permeability transition
regulates some necrotic but not apoptotic cell death. Nature.
434:652–658. 2005.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Katz Sand I: The role of diet in multiple
sclerosis: Mechanistic connections and current evidence. Curr Nutr
Rep. 7:150–160. 2018.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Pathak D, Berthet A and Nakamura K: Energy
failure: Does it contribute to neurodegeneration? Ann Neurol.
74:506–516. 2013.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Lee DH, Gold R and Linker RA: Mechanisms
of oxidative damage in multiple sclerosis and neurodegenerative
diseases: Therapeutic modulation via fumaric acid esters. Int J Mol
Sci. 13:11783–11803. 2012.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Miller ED, Dziedzic A, Saluk-Bijak J and
Bijak M: A review of various antioxidant compounds and their
potential utility as complementary therapy in multiple sclerosis.
Nutrients. 11(1528)2019.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Chen X, Chen R, Guo Z, Li C and Li P: The
preparation and stability of the inclusion complex of astaxanthin
with β-cyclodextrin. Food Chem. 101:1580–1584. 2007.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Kamath BS, Srikanta BM, Dharmesh SM,
Sarada R and Ravishankar GA: Ulcer preventive and antioxidative
properties of astaxanthin from Haematococcus pluvialis. Eur J
Pharmacol. 590:387–395. 2008.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Fathi E, Farahzadi R and Charoudeh HN:
L-carnitine contributes to enhancement of neurogenesis from
mesenchymal stem cells through Wnt/β-catenin and PKA pathway. Exp
Biol Med (Maywood). 242:482–486. 2017.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Zhang XS, Zhang X, Wu Q, Li W, Wang CX,
Xie GB, Zhou XM, Shi JX and Zhou ML: Astaxanthin offers
neuroprotection and reduces neuroinflammation in experimental
subarachnoid hemorrhage. J Surg Res. 192:206–213. 2014.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Grimmig B, Daly L, Subbarayan M, Hudson C,
Williamson R, Nash K and Bickford PC: Astaxanthin is
neuroprotective in an aged mouse model of Parkinson's disease.
Oncotarget. 9:10388–10401. 2017.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Galasso C, Orefice I, Pellone P, Cirino P,
Miele R, Ianora A, Brunet C and Sansone C: On the neuroprotective
role of astaxanthin: New perspectives? Mar Drugs.
16(247)2018.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Speranza L, Pesce M, Patruno A,
Franceschelli S, De Lutiis MA, Grilli A and Felaco M: Astaxanthin
treatment reduced oxidative induced pro-inflammatory cytokines
secretion in U937: SHP-1 as a novel biological target. Mar Drugs.
10:890–899. 2012.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Mix E, Meyer-Rienecker H and Zettl UK:
Animal models of multiple sclerosis for the development and
validation of novel therapies-Potential and limitations. J Neurol.
255 (Suppl 6):S7–S14. 2008.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Silvestroff L, Bartucci S, Pasquini J and
Franco P: Cuprizone-induced demyelination in the rat cerebral
cortex and thyroid hormone effects on cortical remyelination. Exp
Neurol. 235:357–367. 2012.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Zhen W, Liu A, Lu J, Zhang W, Tattersall D
and Wang J: An alternative cuprizone-induced demyelination and
remyelination mouse model. ASN Neuro.
9(1759091417725174)2017.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Stidworthy MF, Genoud S, Suter U, Mantei N
and Franklin RJ: Quantifying the early stages of remyelination
following cuprizone-induced demyelination. Brain Pathol.
13:329–339. 2003.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Lotfi A, Soleimani M and Ghasemi N:
Astaxanthin reduces demyelination and oligodendrocytes death in a
rat model of multiple sclerosis. Cell J. 22:565–571.
2021.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Shen P, Lin W, Deng X, Ba X, Han L, Chen
Z, Qin K, Huang Y and Tu S: Potential Implications of Quercetin in
Autoimmune Diseases. Front Immunol. 12(689044)2021.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Tang SM, Deng XT, Zhou J, Li QP, Ge XX and
Miao L: Pharmacological basis and new insights of quercetin action
in respect to its anti-cancer effects. Biomed Pharmacother.
121(109604)2020.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Santangelo R, Silvestrini A and Mancuso C:
Ginsenosides, catechins, quercetin and gut microbiota: Current
evidence of challenging interactions. Food Chem Toxicol. 123:42–49.
2019.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Dower JI, Geleijnse JM, Gijsbers L,
Schalkwijk C, Kromhout D and Hollman PC: Supplementation of the
pure flavonoids epicatechin and quercetin affects some biomarkers
of endothelial dysfunction and inflammation in (Pre)hypertensive
adults: A randomized double-blind, placebo-controlled, crossover
trial. J Nutr. 145:1459–1463. 2015.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Murakami A, Ashida H and Terao J:
Multitargeted cancer prevention by quercetin. Cancer Lett.
269:315–325. 2008.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Carullo G, Cappello AR, Frattaruolo L,
Badolato M, Armentano B and Aiello F: Quercetin and derivatives:
Useful tools in inflammation and pain management. Future Med Chem.
9:79–93. 2017.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Li G, Shen X, Wei Y, Si X, Deng X and Wang
J: Quercetin reduces Streptococcus suis virulence by inhibiting
suilysin activity and inflammation. Int Immunopharmacol. 69:71–78.
2019.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Ahmed OM, Mohamed T, Moustafa H, Hamdy H,
Ahmed RR and Aboud E: Quercetin and low level laser therapy promote
wound healing process in diabetic rats via structural
reorganization and modulatory effects on inflammation and oxidative
stress. Biomed Pharmacother. 101:58–73. 2018.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Michalski J, Deinzer A, Stich L, Zinser E,
Steinkasserer A and Knippertz I: Quercetin induces an
immunoregulatory phenotype in maturing human dendritic cells.
Immunobiology. 225(151929)2020.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Steinman RM, Hawiger D and Nussenzweig MC:
Tolerogenic dendritic cells. Annu Rev Immunol. 21:685–711.
2003.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Amodio G and Gregori S: Dendritic cells A
double-edge sword in autoimmune responses. Front Immunol.
3(233)2012.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Saadeldin MK, Abdel-Aziz AK and Abdellatif
A: Dendritic cell vaccine immunotherapy; the beginning of the end
of cancer and COVID-19. A hypothesis. Med Hypotheses.
146(110365)2021.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Lin W, Wang W, Wang D and Ling W:
Quercetin protects against atherosclerosis by inhibiting dendritic
cell activation. Mol Nutr Food Res. 61:2017.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Mascanfroni ID, Yeste A, Vieira SM, Burns
EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Efroni S, et al:
IL-27 acts on DCs to suppress the T cell response and autoimmunity
by inducing expression of the immunoregulatory molecule CD39. Nat
Immunol. 14:1054–1063. 2013.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Wu J and Horuzsko A: Expression and
function of immunoglobulin-like transcripts on tolerogenic
dendritic cells. Hum Immunol. 70:353–356. 2009.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Farias AS, Spagnol GS, Bordeaux-Rego P,
Oliveira CO, Fontana AG, de Paula RF, Santos MP, Pradella F, Moraes
AS, Oliveira EC, et al: Vitamin D3 induces IDO+ tolerogenic DCs and
enhances treg, reducing the severity of EAE. CNS Neurosci Ther.
19:269–277. 2013.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Iberg CA, Jones A and Hawiger D: Dendritic
cells as inducers of peripheral tolerance. Trends Immunol.
38:793–804. 2017.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Benson JM and Shepherd DM: Dietary ligands
of the aryl hydrocarbon receptor induce anti-inflammatory and
immunoregulatory effects on murine dendritic cells. Toxicol Sci.
124:327–338. 2011.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Jeuken A, Keser BJ, Khan E, Brouwer A,
Koeman J and Denison MS: Activation of the Ah receptor by extracts
of dietary herbal supplements, vegetables, and fruits. J Agric Food
Chem. 51:5478–5487. 2003.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Hooper LV: You AhR what you eat: Linking
diet and immunity. Cell. 147:489–491. 2011.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Li Y, Innocentin S, Withers DR, Roberts
NA, Gallagher AR, Grigorieva EF, Wilhelm C and Veldhoen M:
Exogenous stimuli maintain intraepithelial lymphocytes via aryl
hydrocarbon receptor activation. Cell. 147:629–640. 2011.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Veldhoen M and Brucklacher-Waldert V:
Dietary influences on intestinal immunity. Nat Rev Immunol.
12:696–708. 2012.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Stockinger B, Di Meglio P, Gialitakis M
and Duarte JH: The aryl hydrocarbon receptor: Multitasking in the
immune system. Annu Rev Immunol. 32:403–432. 2014.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Di Meglio P, Duarte JH, Ahlfors H, Owens
ND, Li Y, Villanova F, Tosi I, Hirota K, Nestle FO, Mrowietz U, et
al: Activation of the aryl hydrocarbon receptor dampens the
severity of inflammatory skin conditions. Immunity. 40:989–1001.
2014.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Nguyen NT, Kimura A, Nakahama T, Chinen I,
Masuda K, Nohara K, Fujii-Kuriyama Y and Kishimoto T: Aryl
hydrocarbon receptor negatively regulates dendritic cell
immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad
Sci USA. 107:19961–19966. 2010.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Kado S, Chang WLW, Chi AN, Wolny M,
Shepherd DM and Vogel CFA: Aryl hydrocarbon receptor signaling
modifies Toll-like receptor-regulated responses in human dendritic
cells. Arch Toxicol. 91:2209–2221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Stockinger B, Hirota K, Duarte J and
Veldhoen M: External influences on the immune system via activation
of the aryl hydrocarbon receptor. Semin Immunol. 23:99–105.
2011.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Huang RY, Yu YL, Cheng WC, OuYang CN, Fu E
and Chu CL: Immunosuppressive Effect of Quercetin on Dendritic Cell
Activation and Function. J Immunol. 184:6815–6821. 2010.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Nickel T, Hanssen H, Sisic Z, Pfeiler S,
Summo C, Schmauss D, Hoster E and Weis M: Immunoregulatory effects
of the flavonol quercetin in vitro and in vivo. Eur J Nutr.
50:163–172. 2011.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Salehi B, Sharifi-Rad J, Cappellini F,
Reiner Z, Zorzan D, Imran M, Sener B, Kilic M, El-Shazly M, Fahmy
NM, et al: The Therapeutic potential of anthocyanins: Current
approaches based on their molecular mechanism of action. Front
Pharmacol. 11(1300)2020.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Mohammadi Pour P, Fakhri S, Asgary S,
Farzaei MH and Echeverría J: The signaling pathways, and
therapeutic targets of antiviral agents: Focusing on the antiviral
approaches and clinical perspectives of anthocyanins in the
management of viral diseases. Front Pharmacol.
10(1207)2019.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Demeilliers C, Toufektsian MC, Salen P,
Laporte F, Petroni K and de Lorgeril M: Ethanol drinking, brain
mitochondrial DNA, polyunsaturated fatty acids and effects of
dietary anthocyanins. Clin Nutr Exp. 12:11–19. 2017.
|
|
153
|
Magni G, Marinelli A, Riccio D, Lecca D,
Tonelli C, Abbracchio MP, Petroni K and Ceruti S: Purple corn
extract as anti-allodynic treatment for trigeminal pain: Role of
microglia. Front Cell Neurosci. 12(378)2018.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Jomova K and Valko M: Advances in
metal-induced oxidative stress and human disease. Toxicology.
383:65–87. 2011.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Speciale A, Anwar S, Canali R, Chirafisi
J, Saija A, Virgili F and Cimino F: Cyanidin-3-O-glucoside counters
the response to TNF-alpha of endothelial cells by activating Nrf2
pathway. Mol Nutr Food Res. 57:1979–1987. 2013.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Zhao M, Wang P, Zhu Y, Liu X, Hu X and
Chen F: Blueberry anthocyanins extract inhibits acrylamide-induced
diverse toxicity in mice by preventing oxidative stress and
cytochrome P450 2E1 activation. J Funct Foods. 14:95–101. 2015.
|
|
157
|
Yin MC, Wang ZH, Liu WH and Mong MC:
Aqueous extract of gynura bicolor attenuated hepatic steatosis,
glycative, oxidative, and inflammatory injury induced by chronic
ethanol consumption in mice. J Food Sci. 82:2746–2751.
2017.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Pham-Huy LA, He H and Pham-Huy C: Free
radicals, antioxidants in disease and health. Int J Biomed Sci.
4:89–96. 2008.PubMed/NCBI
|
|
159
|
Salehi B, Lopez-Jornet P, Pons-Fuster
López E, Calina D, Sharifi-Rad M, Ramírez-Alarcón K, Forman K,
Fernández M, Martorell M, Setzer WN, et al: Plant-derived
bioactives in oral mucosal lesions: A key emphasis to Curcumin,
Lycopene, chamomile, aloe Vera, green tea and coffee properties.
Biomolecules. 9(106)2019.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Hou DX, Yanagita T, Uto T, Masuzaki S and
Fujii M: Anthocyanidins inhibit cyclooxygenase-2 expression in
LPS-evoked macrophages: Structure-activity relationship and
molecular mechanisms involved. Biochem Pharmacol. 70:417–425.
2005.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Theodosis-Nobelos P and Rekka EA: The
multiple sclerosis modulatory potential of natural multi-targeting
antioxidants. Molecules. 27(8402)2022.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Tsuda T, Horio F and Osawa T: Cyanidin
3-O-beta-D-glucoside suppresses nitric oxide production during a
zymosan treatment in rats. J Nutr Sci Vitaminol (Tokyo).
48:305–310. 2002.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Shah SA, Yoon GH and Kim MO: Protection of
the developing brain with anthocyanins against ethanol-induced
oxidative stress and neurodegeneration. Mol Neurobiol.
51:1278–1291. 2015.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Khan MS, Ali T, Kim MW, Jo MH, Jo MG,
Badshah H and Kim MO: Anthocyanins protect against LPS-induced
oxidative stress-mediated neuroinflammation and neurodegeneration
in the adult mouse cortex. Neurochem Int. 100:1–10. 2016.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Aura AM, Martin-Lopez P, O'Leary KA,
Williamson G, Oksman-Caldentey KM, Poutanen K and Santos-Buelga C:
In vitro metabolism of anthocyanins by human gut microflora. Eur J
Nutr. 44:133–142. 2005.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Czank C, Cassidy A, Zhang Q, Morrison DJ,
Preston T, Kroon PA, Botting NP and Kay CD: Human metabolism and
elimination of the anthocyanin, cyanidin-3-glucoside: A 13C-tracer
study. Am J Clin Nutr. 97:995–1003. 2013.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Kay CD, Kroon PA and Cassidy A: The
bioactivity of dietary anthocyanins is likely to be mediated by
their degradation products. Mol Nutr Food Res. 53
(suppl.1):S92–S101. 2009.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Afzal O, Dalhat MH, Altamimi ASA, Rasool
R, Alzarea SI, Almalki WH, Murtaza BN, Iftikhar S, Nadeem S, Nadeem
MS and Kazmi I: Green tea catechins attenuate neurodegenerative
diseases and cognitive deficits. Molecules. 27(7604)2022.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Zhao T, Li C, Wang S and Song X: Green Tea
(Camellia sinensis): A review of its phytochemistry, pharmacology,
and toxicology. Molecules. 27(3909)2022.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Singh NA, Mandal AK and Khan ZA: Potential
neuroprotective properties of epigallocatechin-3-gallate (EGCG).
Nutr J. 15(60)2016.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Aktas O, Prozorovski T, Smorodchenko A,
Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S and
Zipp F: Green tea epigallocatechin-3-gallate mediates T Cellular
NF-kappa B inhibition and exerts neuroprotection in autoimmune
encephalomyelitis. J Immunol. 173:5794–5800. 2004.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Herges K, Millward JM, Hentschel N,
Infante-Duarte C, Aktas O and Zipp F: Neuroprotective effect of
combination therapy of Glatiramer acetate and
epigallocatechin-3-gallate in neuroinflammation. PLoS One.
6(e25456)2011.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Sun Q, Zheng Y, Zhang X, Hu X, Wang Y,
Zhang S, Zhang D and Nie H: Novel immunoregulatory properties of
EGCG on reducing inflammation in EAE. Front Biosci (Landmark Ed).
18:332–342. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
174
|
Grinberg LN, Newmark H, Kitrossky N,
Rahamim E, Chevion M and Rachmilewitz EA: Protective effects of tea
polyphenols against oxidative damage to red blood cells. Biochem
Pharmacol. 54:973–978. 1997.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Nanjo F, Goto K, Seto R, Suzuki M, Sakai M
and Hara Y: Scavenging effects of tea catechins and their
derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic
Biol Med. 21:895–902. 1996.PubMed/NCBI View Article : Google Scholar
|
|
176
|
van Acker SA, van Den Berg DJ, Tromp MN,
Griffioen DH, van Bennekom WP, van der Vijgh WJ and Bast A:
Structural aspects of antioxidant activity of flavonoids. Free
Radic Biol Med. 20:331–342. 1996.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Abd El Mohsen MM, Kuhnle G, Rechner AR,
Schroeter H, Rose S, Jenner P and Rice-Evans CA: Uptake and
metabolism of epicatechin and its access to the brain after oral
ingestion. Free Radic Biol Med. 33:1693–1702. 2002.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Zhang B, Rusciano D and Osborne NN: Orally
administered epigallocatechin gallate attenuates retinal neuronal
death in vivo and light-induced apoptosis in vitro. Brain Res.
1198:141–152. 2008.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Solanki I, Parihar P, Mansuri ML and
Parihar MS: Flavonoid-based therapies in the early management of
neurodegenerative diseases. Adv Nutr. 6:64–72. 2015.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Schroeder EK, Kelsey NA, Doyle J, Breed E,
Bouchard RJ, Loucks FA, Harbison RA and Linseman DA: Green tea
epigallocatechin 3-gallate accumulates in mitochondria and displays
a selective antiapoptotic effect against inducers of mitochondrial
oxidative stress in neurons. Antioxid Redox Signal. 11:469–480.
2009.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Zhang X, Wu M, Lu F, Luo N, He ZP and Yang
H: Involvement of α7 nAChR signaling cascade in epigallocatechin
gallate suppression of β-Amyloid-Induced apoptotic cortical
neuronal insults. Mol Neurobiol. 49:66–77. 2014.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Yao C, Zhang J, Liu G, Chen F and Lin Y:
Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of
stroke is mediated through inhibition of endoplasmic reticulum
stress. Mol Med Rep. 9:69–76. 2014.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Han J, Wang M, Jing X, Shi H, Ren M and
Lou H: (-)-Epigallocatechin gallate protects against cerebral
ischemia-induced oxidative stress via Nrf2/ARE signaling. Neurochem
Res. 39:1292–1299. 2014.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Abib RT, Peres KC, Barbosa AM, Peres TV,
Bernardes A, Zimmermann LM, Quincozes-Santos A, Fiedler HD, Leal
RB, Farina M and Gottfried C: Epigallocatechin-3-gallate protects
rat brain mitochondria against cadmium-induced damage. Food Chem
Toxicol. 49:2618–2623. 2011.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Sagi Y, Mandel S, Amit T and Youdim MB:
Activation of tyrosine kinase receptor signaling pathway by
rasagiline facilitates neurorescue and restoration of nigrostriatal
dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis.
25:35–44. 2007.PubMed/NCBI View Article : Google Scholar
|
|
186
|
Sutherland BA, Shaw OM, Clarkson AN,
Jackson DN, Sammut IA and Appleton I: Neuroprotective effects of
(-)-epigallocatechin gallate Following hypoxia-ischemia-induced
brain damage: Novel mechanisms of action. FASEB J. 19:258–260.
2005.PubMed/NCBI View Article : Google Scholar
|
|
187
|
Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ,
Kim HT, Kim J, Kim MH, Hwang MS, Song C, et al: The effect of
epigallocatechin gallate on suppressing disease progression of ALS
model mice. Neurosci Lett. 395:103–107. 2006.PubMed/NCBI View Article : Google Scholar
|
|
188
|
Rezai-Zadeh K, Shytle D, Sun N, Mori T,
Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, et al:
Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid
precursor protein cleavage and reduces cerebral amyloidosis in
Alzheimer transgenic mice. J Neurosci. 25:8807–8814.
2005.PubMed/NCBI View Article : Google Scholar
|
|
189
|
Ban JY, Jeon SY, Bae K, Song KS and Seong
YH: Catechin and epicatechin from Smilacis chinae rhizome protect
cultured rat cortical neurons against amyloid beta protein
(25-35)-induced neurotoxicity through inhibition of cytosolic
calcium elevation. Life Sci. 79:2251–2259. 2006.PubMed/NCBI View Article : Google Scholar
|
|
190
|
Reznichenko L, Amit T, Youdim MB and
Mandel S: Green tea polyphenol (-)-epigallocatechin-3-gallate
induces neurorescue of long-term serum-deprived PC12 cells and
promotes neurite outgrowth. J Neurochem. 93:1157–1167.
2005.PubMed/NCBI View Article : Google Scholar
|
|
191
|
Pae M, Ren Z, Meydani M, Shang F, Meydani
SN and Wu D: Epigallocatechin-3-gallate directly suppresses T cell
proliferation through impaired IL-2 utilization and cell cycle
progression. J Nutr. 140:1509–1515. 2010.PubMed/NCBI View Article : Google Scholar
|
|
192
|
Wu D, Wang J, Pae M and Meydani SN: Green
tea EGCG, T cells, and T cell-mediated autoimmune diseases. Mol
Aspects Med. 33:107–118. 2012.PubMed/NCBI View Article : Google Scholar
|
|
193
|
Information NC for B. PubChem Compound
Summary for CID 5280343, Quercetin. [Internet]. 2023 [cited 2023
Apr 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/quercetin.
|
|
194
|
Mattioli R, Francioso A, Mosca L and Silva
P: Anthocyanins: A comprehensive review of their chemical
properties and health effects on cardiovascular and
neurodegenerative diseases. Molecules. 25(3809)2020.PubMed/NCBI View Article : Google Scholar
|
|
195
|
National Center for Biotechnology
Information. PubChem Compound Summary for CID 5281224, Astaxanthin.
[Internet]. 2023 [cited 2023 Apr 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Astaxanthin.
|
|
196
|
National Center for Biotechnology
Information. PubChem Compound Summary for CID 65064,
Epigallocatechin Gallate. [Internet]. 2023 [cited 2023 Apr 26].
Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Epigallocatechin-Gallate.
|
